NANTES, France, June 16, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces that the Company is one of the first biotech startup companies selected by ...
OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for LusvertikimabDevelopment built on strong ...
NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces its consolidated half-year financial results and provides updates on key ...
OSE Immunotherapeutics is hoping to show Servier what they walked away from. Around one year after the French drugmakers split up, the biotech has reported midphase data on an anti-IL-7 antibody ...
OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis Lusvertikimab ...
Nantes and Paris - France, January 29, 2025 - 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and Scienta Lab, a leader in Artificial Intelligence (AI)-driven precision ...
Ose Immunotherapeutics is prioritizing its lung cancer med Tedopi and shifting the strategy for its ulcerative colitis (UC) therapy lusvertikimab as the French biotech maps out a financially ...
NANTES, France - March 26, 2025, 6:15 p.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class therapies in immuno-oncology and ...
Republican former Rep. Doug Ose was the seventh major candidate to enter the 2018 governor’s race. He brings the most political experience of the Republicans in the contest. Here are five things you ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results